Intranasal Insulin

Intranasal insulin refers to the delivery of the hormone insulin through the nose, using a spray or specialized nasal device, as a means of getting it into the brain rather than as a way to treat diabetes ^[4]. It is not a distinct chemical; the same recombinant human insulin used for diabetes is administered by a different route ^[3]. The approach is built on the discovery that certain molecules placed high in the nasal cavity can travel directly to the brain along the olfactory and trigeminal nerve pathways, largely bypassing the bloodstream and the blood-brain barrier ^[4].

Interest in the method grew from research linking Alzheimer's disease to disturbed insulin function in the brain, including lower insulin levels in the cerebrospinal fluid, reduced insulin receptor signaling, and brain insulin resistance ^[2]. Because insulin receptors are concentrated in memory-related regions and insulin appears to support synaptic health, investigators proposed that raising brain insulin without flooding the body could benefit cognition ^[2]. This idea gained traction in the 2000s, and the researcher Suzanne Craft and colleagues became prominent in testing it in people with memory disorders ^[3].

Early clinical studies were promising. A pilot trial in adults with amnestic mild cognitive impairment or mild to moderate Alzheimer's disease reported that several months of intranasal insulin improved delayed memory and preserved daily functioning and brain glucose metabolism compared with placebo, without serious side effects ^[3]. Reviews of this early work, together with short-term experiments in healthy volunteers, supported the notion that enhancing brain insulin signaling could aid memory ^[2]. However, a larger, multi-site phase 2 and 3 randomized trial conducted over twelve months found no cognitive or functional benefit in its main analysis, a result complicated by problems with one of the nasal delivery devices used ^[1]. The mixed evidence has left intranasal insulin an active but unproven area of investigation ^[1].

Intranasal insulin remains experimental and is not approved as a treatment for Alzheimer's disease or any other condition; its use is confined to clinical research ^[1]. Beyond dementia, it has been explored in smaller studies for other conditions involving brain metabolism and mood, and the broader nose-to-brain delivery strategy is being pursued for a range of drugs meant to act in the central nervous system ^[4]. A practical challenge is that reaching the brain reliably depends heavily on the delivery device and technique, which has complicated the interpretation of trials ^[1][4].

Generally well tolerated in trials, with the main complaints being minor nasal irritation or rhinitis. Because very little reaches the blood, systemic hypoglycemia is uncommon but can happen with high doses or sloppy technique, so it is worth being mindful if you are diabetic or on glucose-lowering drugs. The honest caveat is the evidence: the large multi-site SNIFF trial found no cognitive benefit in its main cohort (tangled up with nasal-device reliability problems), so this stays genuinely mixed and investigational. Not approved for cognition; this is educational, not medical advice.

Intranasal insulin emerged as a cognition and Alzheimer's research strategy in the early 2000s, built on the finding that intranasal peptides can reach the brain along olfactory pathways; Born and colleagues described this transnasal route in Nature Neuroscience in 2002. Christian Benedict and coworkers in Germany then reported in 2004 and 2007 that intranasal insulin improved memory in healthy adults without altering blood glucose or insulin. Suzanne Craft at the University of Washington and the Seattle VA became a leading investigator, running pilot trials in amnestic mild cognitive impairment and mild Alzheimer's disease that reported gains in memory and attention. Larger Phase 2 trials produced mixed results complicated by differences in nasal delivery devices, and intranasal insulin remains investigational rather than an approved therapy.